Clinical Trial: NCT05969184
Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Peking University Cancer Hospital & Institute |
| Information Provided By: | Peking University Cancer Hospital & Institute |
| Last Update Posted: | 2026-07-15 |
Study Overview
Brief Summary
This study is to find out that if HER-2 positive and HR positive patients could benefit from trastuzumab and pertuzumab combined with palbociclib and endocrine therapy.
Official Title
Palbociclib Combine With Endocrine Therapy and Anti-HER2 Therapy in HR Positive and HER2 Positive Advanced Breast Cancer
Conditions
Breast Neoplasm Female
Intervention / Treatment
- Drug: CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
Other Study ID Numbers
- CABC015
Start Date (Actual)
2021-12-12
Primary Completion Date (Actual)
2026-04-25
Study Completion Date (Actual)
2026-06-25
Enrollment (Actual)
94
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Peking University Cancer Hospital & Institute |
| Information Provided By: | Peking University Cancer Hospital & Institute |
| Last Update Posted: | 2026-07-15 |
Study Overview
Brief Summary
This study is to find out that if HER-2 positive and HR positive patients could benefit from trastuzumab and pertuzumab combined with palbociclib and endocrine therapy.
Official Title
Palbociclib Combine With Endocrine Therapy and Anti-HER2 Therapy in HR Positive and HER2 Positive Advanced Breast Cancer
Conditions
Breast Neoplasm Female
Intervention / Treatment
- Drug: CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
Other Study ID Numbers
- CABC015
Start Date (Actual)
2021-12-12
Primary Completion Date (Actual)
2026-04-25
Study Completion Date (Actual)
2026-06-25
Enrollment (Actual)
94
Study Type
Interventional
Phase
Phase 2